This company listing is no longer active
ISR Immune System Regulation Holding Past Earnings Performance
Past criteria checks 0/6
Key information
-57.2%
Earnings growth rate
-28.7%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 98.2% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
We're Not Very Worried About ISR Immune System Regulation Holding's (STO:ISR) Cash Burn Rate
Aug 11
A Look At The Fair Value Of ISR Immune System Regulation Holding AB (publ) (STO:ISR)
Jul 02Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Mar 08Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Nov 18Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Jul 27Here's Why We're Watching ISR Immune System Regulation Holding's (STO:ISR) Cash Burn Situation
Mar 26We Think ISR Immune System Regulation Holding (STO:ISR) Can Afford To Drive Business Growth
Dec 11
Revenue & Expenses Breakdown
How ISR Immune System Regulation Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -213 | 24 | 179 |
| 30 Sep 22 | 0 | -235 | 26 | 203 |
| 30 Jun 22 | 0 | -257 | 29 | 226 |
| 31 Mar 22 | 0 | -168 | 26 | 141 |
| 31 Dec 21 | 0 | -79 | 22 | 56 |
| 30 Sep 21 | 0 | -60 | 20 | 40 |
| 30 Jun 21 | 0 | -41 | 18 | 24 |
| 31 Mar 21 | 0 | -36 | 16 | 20 |
| 31 Dec 20 | 0 | -31 | 14 | 16 |
| 30 Sep 20 | 0 | -29 | 13 | 15 |
| 30 Jun 20 | 0 | -28 | 12 | 14 |
| 31 Mar 20 | 0 | -28 | 13 | 15 |
| 31 Dec 19 | 0 | -29 | 13 | 16 |
| 30 Sep 19 | 0 | -29 | 14 | 15 |
| 30 Jun 19 | 0 | -28 | 14 | 14 |
| 31 Mar 19 | 0 | -25 | 12 | 12 |
| 31 Dec 18 | 0 | -21 | 11 | 10 |
| 30 Sep 18 | 0 | -20 | 13 | 19 |
| 30 Jun 18 | 0 | -18 | 11 | 17 |
| 31 Mar 18 | 0 | -18 | 10 | 14 |
| 31 Dec 17 | 0 | -21 | 9 | 12 |
| 30 Sep 17 | 0 | -30 | 1 | 0 |
| 30 Jun 17 | 0 | -21 | 4 | 0 |
| 31 Mar 17 | 0 | -27 | 2 | 0 |
| 31 Dec 16 | 0 | -14 | 5 | 0 |
Quality Earnings: ISR is currently unprofitable.
Growing Profit Margin: ISR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ISR is unprofitable, and losses have increased over the past 5 years at a rate of 57.2% per year.
Accelerating Growth: Unable to compare ISR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ISR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.9%).
Return on Equity
High ROE: ISR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/12 04:27 |
| End of Day Share Price | 2022/12/13 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ISR Immune System Regulation Holding AB (publ) is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ethel Szpilman Luvall | Redeye |